Through this symposium, we will discuss the latest updates from the 2024 ASCO congress. Recent advances in the treatment of non-small cell lung cancer (NSCLC) with HER2 alterations have introduced novel therapies and improved patient outcomes. Innovative drugs, including HER2 inhibitors and antibody-drug conjugates, have demonstrated significant efficacy in clinical trials, offering new hope for this patient subset. In small cell lung cancer (SCLC), we will explore the latest advancements in the treatment of SCLC. Topics will include the integration of immune checkpoint inhibitors and novel mechanism agents into clinical practice. across different stages of SCLC.